<DOC>
	<DOCNO>NCT00845559</DOCNO>
	<brief_summary>The primary aim study evaluate effect exenatide daily glycemic excursion obtain continuous glucose monitoring system ( CGMS ) . The CGMS summary parameter interested include : - The percent glucose value 140 mg/dl and/or AUC glucose value 140 mg/dl - AUC glucose value 100 mg/dl three day - Maximal meal-related glucose excursion - Three-day mean glucose ( include low reading - 100 mg/dl ) Secondary Study Endpoints : Secondary endpoint include : - glucose tolerance status assess OGTT - Vascular function score assess PAT , FMD step test . - Biochemical marker vascular health , include inflammatory marker , marker oxidative stress microalbuminuria . - Changes BMI</brief_summary>
	<brief_title>The Effects Exenatide Post-Meal Sugar Peaks Vascular Health Obese/Pre-Diabetic Young Adults</brief_title>
	<detailed_description>Obese insulin resistant adolescent impair glucose tolerance ( IGT ) evidence glucose excursion ≥ 140 mg/dl CGMS enrol two armed randomize , parallel group - open label study . There also lean control group baseline assessment . One arm exenatide arm drug . Subjects stratify accord state glucose tolerance . Stratification also occur accord gender family history premature cardiovascular disease . Obese adolescent age 16-25 year family history type 2 diabetes , complete reach tanner IV stage pubertal development normal impaired oral glucose tolerance . Obese adolescent age 13-15 family history type 2 diabetes , complete reach tanner III stage pubertal development impair oral glucose tolerance 2-hour glucose 180-199 mg/dl also invite participate . For cardiovascular assessment age match lean control subject without diabetes recruit . Obese subject baseline post intervention oral glucose tolerance test ( OGTT ) , screen lab ( liver/kidney function , lipid profile , thyroid function test , CBC , metabolic cardiovascular laboratory parameter -- inflammatory cytokine pro-thrombotic factor ) , wear CGMS 3-days 3 separate occasion ( baseline , 2-month 4-month ) , standardize snack CGMS session , collect urine sample microalbumin vascular test ( PAT , FMD exercise step test ) do baseline post intervention . Subjects randomized treatment undergo four month intervention exenatide follow dose schedule : exenatide - 5 μg twice day 7 day , follow exenatide 10 μg twice day remainder four month intervention . Lean Control Subjects : As obese subject , lean subject ask bring first morning void test microalbuminuria . They also endothelial function test ( PAT , FMD step test ) well CGMS placement . A set screening lab also draw ( fast glucose , insulin , thyroid function lipid profile drawn ) . Furthermore blood collect analysis novel cardiovascular parameter ( inflammatory cytokine pro-thrombotic factor ) . However lean subject OGTT do offer drug intervention . The endothelial function test lean control serve control data vascular function test obese child . The CGMS data lean control allow u good interpret change post-meal excursion see obese child exenatide intervention . Similar obese subject , lean subject instruct take standardized snack afternoon prior return CGMS removal . The snack provide take home end CGMS placement visit include two pop-tarts orange soda . Lean control subject wear CGMS three day . At end monitoring period subject return CGMS removal visit .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Obese subject : Major Obesity ( BMI &gt; 97 % tile age sex match normative data ) Insulin resistance : fasting insulin &gt; 25 mIU/ml Good general health , take medication chronic basis Age 1625 yr , late pubertal stage ( girl : breast : Tanner stage IV V , boys : testicular volume &gt; 15 ml ) age 1315 yr ( family history type 2 diabetes , complete reach tanner stage III impair oral glucose tolerance 2hour glucose 180199 mg/dl ) Girls sexually active must use adequate birth control method ( barrier method oral contraception ) must negative pregnancy test Normal liver function test Major Hx gallstone Elevated triglyceride &gt; 400 mg/dl Hx alcohol use/ binge drink Raynaud 's syndrome Pregnancy breastfeed mother Cigarette smoker Anemia ( Hct &lt; 35 ) Baseline creatinine &gt; 1.0 mg Abnormal liver transaminases &gt; 2.0 X upper limit normal Presence endocrinopathies except adequately treated hypothyroidism Presence history gastrointestinal disorder ( inflammatory bowl disease , irritable bowl disease , hernia , ileus ) Presence significant chronic illness kind . Use drug might expect affect glucose tolerance , insulin resistance weight gain , cardiovascular health . Psychiatric disorder History substance abuse Lean Control Subjects ( cardiovascular study CGMS ) : Lean ( BMI &lt; 85 % tile age sex match normative data ) Fasting insulin &lt; 15 mIU/m Fasting glucose &lt; 100 mg/dll Excellent general health , acute chronic health problem take current medication Age 1325 yr , puberty ( age match obese subject ) Girls sexually active must use adequate birth control method ( barrier method oral contraception ) must negative pregnancy test Raynaud 's syndrome Pregnancy breastfeed mother Cigarette smoker Psychiatric disorder History substance abuse First degree relative either T1DM T2DM Presence acanthosis nigricans</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Childhood Obesity</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Impaired Glucose Tolerance</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Continuous Glucose Monitoring ( CGMS )</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Oral Glucose Tolerance Test</keyword>
</DOC>